APP
ABMD

Avantax Planning Partners’s Abiomed Inc ABMD Stock Holding History

Avantax Planning Partners’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-25
Closed -$7K – 1613
2018
Q1 		$7K Buy
+25
New +$6.34K ﹤0.01% 1229

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Avantax Planning Partners's ABMD Position: Q2 2018 in Review

Avantax Planning Partners sold out of Abiomed Inc (ABMD) in Q2 2018, closing a stake of 25 shares — an estimated $7K sold.

Avantax Planning Partners first reported a position in ABMD in Q1 2018 and held it in 1 quarter. The position peaked at $7K in Q1 2018. 527 funds tracked by Wall St. Rank hold ABMD as of Q2 2018.

  • Avantax Planning Partners reported no remaining Abiomed Inc position as of Q2 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 25 Abiomed Inc shares in Q2 2018, an estimated $7K.
  • Avantax Planning Partners first reported a position in Abiomed Inc in Q1 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Abiomed Inc position peaked at $7K in Q1 2018.
  • 527 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2018.

Based on Avantax Planning Partners's 13F filing for Q2 2018, filed 13 Aug 2018.